The IRMA Community
Newsletters
Research IRM
Click a keyword to search titles using our InfoSci-OnDemand powered search:
|
Corporate Social Responsibility of Pharmaceutical Industry Towards Access to Medicine: A Case Study of GlaxoSmithKline
Abstract
India has changed its patent policy in 2005. It was compliance to WTO TRIPs provision and after this there was prohibition on process or generic manufacturing. India is the biggest supplier of affordable generic medicines and this patent protection is said to be beneficial to novel drug manufacturing countries. The generic drugs can be a differentiation factor between lives starting point and the ending point for millions of people in developing countries. This remains an obstacle to inexpensive generic medicines which results in devastating impact on the poorer people. These patent laws allow large MNC's to place ‘profits over people'. World Health Organisation report price of medicines are important for maintaining the affordability and access of the medicines. This research evaluates the strategies and practices of Glaxo Smith Kline in contribution towards the access to medicines and their contribution of corporate social responsibility in India.
Related Content
|
Edward Mudzimba, Fainos Chokera, Mercy Dube.
© 2024.
23 pages.
|
|
Ricardo Jorge Silva, Paulo Botelho Pires, Catarina Delgado, José Duarte Santos.
© 2024.
24 pages.
|
|
Veronika Keller, Ida Ercsey.
© 2024.
20 pages.
|
|
Ana Isabel Canavarro, Susana Cristina Santos, Joana Vagaroso Tiago.
© 2024.
8 pages.
|
|
Gonzalo Díaz Meneses, Sol Castellanos Pérez Lasala, Maica Amador-Marrero.
© 2024.
28 pages.
|
|
Jamie Neil Coles.
© 2024.
19 pages.
|
|
Edna Mngusughun Denga.
© 2024.
20 pages.
|
|
|